Inhibitory mechanism of dipyridamole on platelet aggregation ex vivo.
The effects of dipyridamole on platelet aggregation ex vivo and in vitro and on platelet cyclic AMP phosphodiesterase (PDE) were studied, and the mechanism of the ex vivo effects was assessed. Both the ADP- and collagen-induced aggregations ex vivo were inhibited dose-responsively by oral administration of dipyridamole. Maximum dipyridamole levels in the plasma were reached at 30 min after the administration. The inhibitory effects of dipyridamole on platelet aggregation ex vivo reached a maximum at between 1 and 2 hrs. On the other hand, the ADP-induced aggregation in vitro and cyclic AMP PDE activity were not inhibited until after 10 min of incubation at a low concentration of dipyridamole. This mode of inhibition of platelet aggregation in vitro and of cyclic AMP PDE activity agreed with the mode of inhibition in the case of platelet aggregation ex vivo. It is suggested therefore that the ex vivo effects, observed with only a low dipyridamole concentration in the plasma, may be due primarily to inhibition by dipyridamole of the cyclic AMP PDE in platelets.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D003094:Collagen / Q000494:pharmacology; D000242:Cyclic AMP / Q000037:antagonists & inhibitors; D003864:Depression, Chemical; D004176:Dipyridamole / Q000097:blood / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D013997:Time Factors
D010726:Phosphodiesterase Inhibitors; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D003094:Collagen; D000242:Cyclic AMP